Inflammation clinical trial in mild to moderate Alzheimer's disease: TSPO‐PET results
While IL-2 immunotherapy every 4 weeks enhanced Treg populations, showing promising trends in AD biomarkers and clinical scales, TSPO-PET was largely unchanged over the 21 weeks of the trial. A longer follow-up period, a larger sample size, or, more likely, PET tracers specific for M1 and M2 macrophages or other inflammation targets are needed for future clinical trials.
Authors
- Belén Pascual (ORCID: https://orcid.org/0000-0002-4467-7406)
- Joseph C. Masdeu (ORCID: https://orcid.org/0000-0001-9955-6954)
- Alireza Faridar
- Nazaret Gamez (ORCID: https://orcid.org/0000-0001-6847-7735)
- Quentin Finn
- Stanley H Appel
Institutions
- Houston Methodist (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_103463
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00